Trial Profile
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2026
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Cabotegravir+rilpivirine (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary) ; Integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS
- Sponsors ViiV Healthcare
Most Recent Events
- 31 Dec 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2029.
- 22 Jan 2025 Planned End Date changed from 31 Dec 2026 to 31 Dec 2025.
- 22 Dec 2023 Results of post-hoc analysis cabotegravir plus rilpivirine long-acting results by baseline body mass index (BMI) category among patients from FLAIR, ATLAS, and ATLAS-2 M trials pooled through Week (W) 48, published in the Journal of Infectious Diseases.